title: Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients.
abstract: Once-yearly administration of intravenous zoledronic acid for 3 years in humans affects the kinetics of matrix filling in by mineral, independent of bone turnover.
  
  
  BACKGROUND
  Yearly 5-mg infusions of zoledronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation.
  
  
  METHODS
  Iliac crest biopsies from the HORIZON-PFT clinical trial were analyzed by Raman microspectroscopy in actively bone-forming surfaces as a function of tissue age in trabecular and osteonal bone, to determine ZOL's effect on bone material quality indices maturation kinetics.
  
  
  RESULTS
  Mineral/matrix ratio increased in both groups as a function of tissue age, at both osteonal- and trabecular-forming surfaces; ZOL exhibiting the greatest increase in the trabecular surfaces only. The proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with ZOL exhibiting lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (crystallite length and thickness) showed a dependence on tissue age, with ZOL exhibiting lower crystallite length compared with placebo only in the 8- to 22-day-old tissue at trabecular surfaces, while crystal thickness was lower in the 1- to 5-day-old tissue at both osteonal and trabecular surfaces.
  
  
  CONCLUSIONS
  The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any adverse effects on the evolution of bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral-to-matrix ratio and mineral maturity bone quality indices.
authors.affiliation: Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, 1140, Vienna, Austria. sonja.gamsjaeger@osteologie.at
authors.forename: S
authors.initials: S
authors.lastname: Gamsjaeger
authors.forename: B
authors.initials: B
authors.lastname: Hofstetter
authors.forename: E
authors.initials: E
authors.lastname: Zwettler
authors.forename: R
authors.initials: R
authors.lastname: Recker
authors.forename: J A
authors.initials: JA
authors.lastname: Gasser
authors.forename: E F
authors.initials: EF
authors.lastname: Eriksen
authors.forename: K
authors.initials: K
authors.lastname: Klaushofer
authors.forename: E P
authors.initials: EP
authors.lastname: Paschalis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001857:Bone Matrix / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011509:Proteoglycans / Q000378:metabolism; D013059:Spectrum Analysis, Raman / Q000379:methods; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D011509:Proteoglycans; D000077211:Zoledronic Acid